GS-030 is under clinical development by GenSight Biologics and currently in Phase II for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase II drugs for Retinitis Pigmentosa (Retinitis) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GS-030’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GS-030 overview
GS-030 is under development for the treatment of retinitis pigmentosa, geographic atrophy in dry age-related macular degeneration.. It is administered through subretinal and intravitreal routes. GS-030 is based on optogenetics technology therapy where ChrimsonR-tdTomato gene is embedded into a specific AAV2 7m8 (adeno associated virus) variant in cone cells under the control of the ubiquitous CAG promoter.
GenSight Biologics overview
GenSight Biologics (GenSight) is a clinical-stage biotechnology company. It discovers and develops novel therapies for mitochondrial and eye neurodegenerative diseases. The company’s product pipeline comprises GS010 and GS030 developed for the treatment of retinal degenerative diseases. It develops solutions for preserving vision in patients suffering from very low vision or blindness due to degenerative retinal and inherited ophthalmologic diseases. GenSight’s drugs target gene replacement therapy for vision loss in leber hereditary optic neuropathy. It also develops products for retinitis pigmentosa and other hereditary diseases of the retina. GenSight is headquartered in Paris, Ile-de-France, France.
For a complete picture of GS-030’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
